{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:20:24Z","timestamp":1737696024510,"version":"3.33.0"},"reference-count":0,"publisher":"African Journals Online (AJOL)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["gmj"],"abstract":"<jats:p>Objective: This study aims to evaluate the ancillary benefit of intermittent preventive therapy with sulfadoxine-pyrimethamine ( IPTp-SP) in preventing maternal anaemia (MA) among parturient women differentially exposed to the regimen.Design: A health facility-based retrospective analytical cross-sectional study.Settings: The study was conducted at the Kade Government Hospital\u2019s maternity\/labor suit.Participants: Data from 2,545 parturient women were abstracted from birth registers.Statistical analysis: Baseline characteristics were described, and stratified analyses assessed their impacts. Differences in mean mHgbc based on IPTp-SP exposure were determined using one-way ANOVA. An unpaired two-sample t-test evaluated the significance of inter-dose group differences. The bivariable analysis examined crude and adjusted risks of anaemia with differential IPTp-SP exposure.Main outcome measure: The main outcome measure was the level of mHgbc with varying IPTp-SP exposure.Results: The overall mean exposure to IPTp-SP was 2.35 (\u00b12.35) doses. Of the women, 5.9% had \u2018nil\u2019 exposure, with a mean mHgbc of 9.71 g\/dL (\u00b11.6). Among the 75.9% who received 1-3 doses, the mean mHgbc was 10.39 g\/dL (\u00b11.3). For the 18.2% who received \u22654 doses, the mean mHgbc was 10.77 g\/dL (\u00b11.4). The mHgbc notably rose as the mean doses of IPTp-SP increased. The crude odds ratios (COR) were 1.96 (95% CI: 0.99-3.89, p = 0.06) for \u2018nil\u2019 exposure, 1.28 (95% CI: 0.92-1.78, p = 0.16) for 1-3 doses, and 0.59 (95% CI: 0.41-0.84, p = 0.002) for \u22654 doses.Conclusion: The consistent linear increase in mean mHgbc with higher IPTp-SP doses remains clinically crucial.<\/jats:p>","DOI":"10.4314\/gmj.v58i4.4","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:50:11Z","timestamp":1737643811000},"page":"269-278","source":"Crossref","is-referenced-by-count":0,"title":["A health facility-based assessment of the ancillary benefit for prevention of anaemia at term of intermittent preventive therapy with sulfadoxine-pyrimethamine in pregnancy"],"prefix":"10.4314","volume":"58","author":[{"given":"Brainard","family":"A. Asare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Asare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2895","published-online":{"date-parts":[[2025,1,10]]},"container-title":["Ghana Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.ajol.info\/index.php\/gmj\/article\/download\/285760\/269229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajol.info\/index.php\/gmj\/article\/download\/285760\/269229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:50:20Z","timestamp":1737643820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajol.info\/index.php\/gmj\/article\/view\/285760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,10]]}},"URL":"https:\/\/doi.org\/10.4314\/gmj.v58i4.4","relation":{},"ISSN":["0016-9560"],"issn-type":[{"value":"0016-9560","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,10]]}}}